The DOI matches its Crossref record.
Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term Results
Open accessAbstract
This study examined alemtuzumab (anti-CD 52, Campath-1H) and basiliximab (anti-CD 25, Simulect) as induction immunosuppression in kidney transplantation. We used a single-center, nonrandomized, retrospective, sequential study design to evaluate outcomes in kidney transplant recipients given either alemtuzumab (n = 123) or basiliximab (n = 155) induction in combination with a prednisone-free maintenance protocol using tacrolimus and mycophenolate mofetil. Kaplan-Meier analyses of long-term patient and graft survivals and rejection rates were determined according to induction agent, donor source and recipient ethnicity. Secondary endpoints included the quality of renal allograft function and the etiology of infectious complications. Overall long-term patient and graft survival rates did not significantly differ between patients treated with alemtuzumab and basiliximab. A lower rate of early (<3 months) rejection was observed in the alemtuzumab (4.1%) versus the basiliximab (11.6%) group, but the rates for both groups were equivalent at 1 year. Patient and kidney survival and rejection rates were nearly identical between Caucasians and African Americans that received alemtuzumab. Quality of renal function and incidence of infectious complications were similar in the two groups. Alemtuzumab induction therapy was similar in efficacy to basiliximab in a prednisone-free maintenance immunosuppressive protocol for an ethnically diverse population of kidney transplant recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alemtuzumab Induction in Renal Transplantation
Hanaway, M. J., Woodle, E. S., Mulgaonkar, S., Peddi, V. R., Kaufman, D. B., First, M. R., Croy, R., & Holman, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009546 · Cited by 383
Self-citationVincenti, F., Schena, F. P., Paraskevas, S., Hauser, I. A., Walker, R. G., & Grinyo, J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02057.x · Cited by 316
Steroid avoidance or withdrawal for kidney transplant recipients
Haller, M. C., Royuela, A., Nagler, E. V., Pascual, J., & Webster, A. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005632.pub3 · Cited by 258
Short-term results under three different immunosuppressive regimens at one center
Schaefer, H. M., Kizilisik, A. T., Feurer, I., Nylander, W. A., Langone, A. J., Helderman, J. H., & Shaffer, D. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.10.098 · Cited by 20
Metadata
- Authors
- Kaufman, D. B., Leventhal, J. R., Axelrod, D., Gallon, L. G., Parker, M. A., & Stuart, F. P.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 5
- Issue
- 10
- Pages
- 2539-2548
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2070333986
- Cited by
- 186
- References
- 0
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term Results. https://app.cochat.ai/papers/10.1111/j.1600-6143.2005.01067.x
- The paper
- Kaufman, D. B., Leventhal, J. R., Axelrod, D., Gallon, L. G., Parker, M. A., & Stuart, F. P. (2005). Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term Results. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2005.01067.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.